










































Novel Circulating miRNA Signatures for Early Detection
of Pancreatic Neoplasia
Elena Vila-Navarro, PhD1, Saray Duran-Sanchon, PhD1, Maria Vila-Casadesús, PhD1,2, Leticia Moreira, MD, PhD1,
Àngels Ginès, MD, PhD1, Miriam Cuatrecasas, MD, PhD1,3, Juan José Lozano, PhD1,2, Luis Bujanda, MD, PhD4,
Antoni Castells, MD, PhD1 and Meritxell Gironella, PhD1
OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) presents the lowest survival rate of all cancers because only
6% of patients reach five-year survival. Alterations in the expression of several microRNAs (miRNAs)
occur in the tumor of PDAC and in preneoplastic lesions as the called intraductal papillary mucinous
neoplasm (IPMN).Here, we aimed at identifyingwhichmiRNAs are significantly altered in liquidbiopsies
from patients with PDAC and IPMN to find new noninvasive biomarkers for early detection of PDAC.
METHODS: We analyzed by real-time quantitative reverse transcription-PCR (qRT-PCR) the expression of 17
circulatingmiRNAs, previously found to be significantly overexpressed in tissue pancreatic neoplasms,
in a set of 182 plasma samples (94 PDAC, 19 IPMN, 18 chronic pancreatitis, and 51 disease-free
controls). Then, we analyzed CA19.9 levels in the same plasma set, and we assessed the diagnostic
values of differentially expressed miRNAs, CA19.9, and all possible combinations.
RESULTS: Of note, 16, 14, and 9 miRNAs were significantly increased in PDAC, IPMN, and chronic pancreatitis,
respectively, compared with control plasmas. miR-21-5p, miR-33a-3p, miR-320a, and miR-93-5p
showed the highest discriminating capacity for pancreatic neoplasia (PDAC or IPMN) with an area under
the receiver operating characteristic curve (AUC) of 0.86, 0.85, 0.85, and 0.80, respectively. 2-miRNA
combinations improved these performances reaching AUC5 0.90 for “miR-33a-3p1miR-320a.”
Addition ofCA19.9 increased the diagnostic potential ofmiRNA signatures even further achieving anAUC
of0.95 (93%sensitivity and85%specificity) for thecombinationof “miR-33a-3p1miR-320a1CA19.9.”
CONCLUSIONS: Novel signatures combining miRNAs and CA19.9 could be used as noninvasive biomarkers for early
detection of PDAC.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A25, http://links.lww.com/CTG/A26, http://links.lww.com/CTG/A27, http://links.
lww.com/CTG/A28, http://links.lww.com/CTG/A29
Clinical and Translational Gastroenterology 2019;10:e-00029. https://doi.org/10.14309/ctg.0000000000000029
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) presents the
lowest survival rate of all cancers because only 6% of patients
having this deadly malignancy survive 5 years or more after
their diagnosis (1). Its poor prognosis has remained almost
the same in the last decades, and PDAC has been predicted to
become the second cause of cancer-related deaths in de-
veloped countries by 2030 (2). PDAC progresses with no
noticeable symptoms in the early stages; thus, approximately
80% of cases are surgically unresectable at the time of di-
agnosis (3).
Althoughmany biochemical markers have been examined in
pancreatic cancer, none are useful for diagnosis in daily practice.
Serum carbohydrate antigen 19.9 (CA19.9), used formonitoring
response to therapy and predicting postoperative recurrence,
has several limitations. It has limited sensitivity and specificity
for PDAC diagnosis, it can be elevated in patients with non-
malignant obstructive jaundice resulting in impaired specificity,
and it is often normal in precancerous masses (4,5). Moreover,
this marker is unsuitable for 10% of the white population who
are unable to express CA19.9 because it is Lewis genotype
negative (6).
1Gastrointestinal & Pancreatic Oncology Group, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD)/Hospital Clínic
of Barcelona/Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain; 2Bioinformatics Platform,
CIBEREHD, Barcelona, Spain; 3Pathology Department, Hospital Clínic of Barcelona, Tumour Bank IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain;
4Department of Gastroenterology, Hospital Donostia/Instituto Biodonostia, CIBEREHD, Universidad del País Vasco UPV/EHU, San Sebastián, Spain.
Correspondence:Meritxell Gironella, PhD. E-mail: meritxell.gironella@ciberehd.org.
Received September 27, 2018; accepted February 22, 2019; published online April 15, 2019
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology









The dire prognosis of patients with PDACand lack of sensitive
and specific tumor markers urges us to find novel noninvasive
biomarkers for an early effective detection of PDAC. To this end,
our study focuses on identifying circulating microRNAs (miR-
NAs) altered in the onset of pancreatic cancer with relevant di-
agnostic characteristics.
Some miRNAs, short-length, noncoding RNAs that post-
transcriptionally regulate gene expression, have been largely found
deregulated in different stages of pancreatic cancer and in the pre-
neoplastic cystic lesion, intraductal papillary mucinous neoplasm
(IPMN) (7,8). This fact, alongwith the following intrinsic features of
miRNAs, could confer these molecules the potential to be reliable
biomarkers.MiRNAs,whose sequences are conservedacross species,
are very stable and resistant to RNAses among other harsh con-
ditions such as extended storage ormultiple freeze-thaw cycles. They
are easily detectable in challenging samples by highly sensitive
techniques and have been found in most body fluids (9,10).
In a previous study, we analyzed the miRNome of PDAC and
IPMN tissues by next-generation sequencing. Subsequently, we
validated a significant increased expression of 30 miRNAs by
qRT-PCR in 2 independent sets of samples (11). MiRNA candi-
dates extracted from these data have been used in the present
multicenter study to identify new noninvasive biomarkers for
early detection of pancreatic cancer.
METHODS
Study design and blood sample collection
A total of 190 subjects from 2 Spanish hospitals (168 from Hos-
pital Clinic of Barcelona, Catalonia, and 22 from Hospital
Donostia, Guipúzcua) were prospectively recruited from January
2009 to September 2013. A group of 96 patients were diagnosed
with PDAC, 20 with IPMN, and 23 with chronic pancreatitis
(CP), and 51 were control individuals (C). Controls were healthy
subjects with no history of any cancer. From all these subjects, we
obtained 10 mL of peripheral venous blood in sterile ethyl-
enediaminetetraacetic acid–treated anticoagulant (K2EDTA)
tubes (BD Vacutainer, Toronto, Canada) before resection or any
treatment. Blood samples were kept on ice during transportation
and immediately processed for plasma separation.
Eight subjects werefinally discarded for the study owing to low
miRNA extraction efficiency as detected by spiked-in cel-miR-39
levels (n 5 6) and to the presence of hemolysis (n 5 2). Clini-
copathologic characteristics of participants in this study are
summarized in Table S1 (see Supplementary Digital Content 2,
http://links.lww.com/CTG/A26). The Institutional Ethics Com-
mittee of Hospital Clinic of Barcelona approved the study (March
27, 2008), and written informed consent was obtained from all
patients in accordance with the Declaration of Helsinki.
Fromour previous study (11), we selected 17 candidatemiRNAs
based on the following criteria: significantly overexpressed in both
PDAC and IPMN vs healthy pancreatic tissues, high discriminative
capacity between PDAC or IPMN and healthy (considering areas
under the receiver operating characteristic (ROC) curves for PDAC
(AUC) . 0.82), and high expression levels in tissue assuring de-
tectable expression levels in the circulation (with mean cycle
threshold (Ct) values# 28, with the exception ofmiR-548d-3p that
presented mean Ct. 30 but a high AUC5 0.93).
Plasma processing
Blood samples were centrifuged at 1,600g for 10 minutes at 4 °C.
The superior phase, which contains the plasma, was transferred
into new tubes and centrifuged at 16,000g for 10 minutes at 4 °C.
The resultant supernatant of plasma poor in platelets was col-
lected and kept at280 °C until RNA extraction.
RNA extraction
Total RNA was isolated from 500 mL plasma by using the miR-
Neasy Mini Kit (Qiagen, Hilden, Germany), following the man-
ufacturers protocol with some variations in the initial steps.
Denaturation of plasma was achieved by TRIzol LS Reagent
(Thermo Fisher Scientific, Foster City, CA), and during its in-
cubation, we added 5 mL of spike-in cel-miR-39 (5 nM) as a ref-
erence for normalization of technical variations between samples.
The elution volume with RNAse-free water was 30 mL.
Analysis of miRNA expression by real-time qRT-PCR
MiRNA expression was assessed by singleplex qRT-PCR using
TaqMan miRNA Assays (Thermo Fisher Scientific) according to
the manufacturer protocol. Considering the general low levels of
miRNAs in plasma, the amount of input RNA per reaction was
standardized by extracting RNA from exactly the same plasma
volume. PCRreactionswere prepared in a 384-well optical plate and
runon theViiA7Real-TimePCRSystem(ThermoFisher Scientific)
with the following program: polymerase activation at 95 °C for 10
minutes and aPCRof 50 cycles at 95 °C for 15 seconds and 60 °C for
1 minute. Negative controls did not show any amplification. All
sampleswere amplifiedper duplicate.Datawere normalized against
cel-miR-39 as the technical control. Currently, there is no consensus
on a suitable endogenous reference miRNA (12). Ct values were
calculated from automatic threshold using QuantStudio Real Time
PCR Software. Preamplification reaction was only performed for
miR-548d-3p because its expression levels in plasma were very low
or undetectable by qRT-PCR. This reaction consisted of 14 cycles of
preamplification using TaqMan PreAmp Master Mix (Thermo
Fisher Scientific). The preamplified product was diluted 1/2 and
analyzed by qRT-PCR as indicated earlier.
Hemolysis assessment
Sample hemolysis can affect plasma miRNA levels because of
miRNA contamination from red blood cells (13,14). Therefore,
hemolyzed samples were discarded before RNA isolation, and
confirmation was done by qRT-PCR quantification of miR-451-
5p. Samples found with high miR-451 levels were classified as
hemolyzed and also discarded.
Detection of plasma CA19.9
CA19.9 levels in plasma were determined by an electro-
chemiluminescent technique in a Cobas 4000 analyzer (Roche
Diagnostics, Indianapolis, IN), considering as normal those
concentrations equal to or below 37 U/mL.
Data analysis
Relative expression levels ofmiRNAswere calculated as (2ΔCt5
2(Ct of specific miRNA – Ct of spike-in control cel-miR-39)).
Fold change values were transformed to a log2 scale, and a t test
was applied. The false discovery rate (FDR) was computed using
the Benjamini & Hochberg procedure (FDR, 0.05 is considered
as significant). Heatmaps or scatter plots, 3D, were done by using
made4 R-package. Evaluation of predictability of miRNAs was
performed using logistic regression adjusted by age and sex
(generalized linear model binomial distribution). ROC analysis
plots and derived cut-points, as well as overall discriminative









accuracy parameters, were computed using pROC R-package
considering each miRNA expression as a continuous variable.
Sensitivity and specificity were calculated from the optimum cut-
point associated with the minimum distance between the ROC
curve and upper left corner. All possible combinations of miR-
NAs were computed withmultivariate logistic regressionmodels,
and ROC AUCs of miRNA signatures were calculated using
samples with no missing values and sorted with the Brier score.
From multivariate analysis, we can see whether miRNAs in the
model are correlated or are independent variables. To compute
the maximum number of variables to be used in the models, we
followed the rule of “10 events per variable considering the n from
the smallest group (n 5 51)” to prevent overfitting. Taking into
account that models were adjusted by age and sex, we considered
that the maximum number of miRNAs and/or CA19.9 to put in
the models was 3. For cross-validation, we computed Harrell
optimism using 5-fold cross-validation and 1,000 resamples.
Predicted risk score probability for each sample was computed
frommultivariate logistic regressionmodel, and these valueswere
used to derive their respective box plots.
RESULTS
qRT-PCRconfirms overexpression of a group of selectedmiRNAs
in the circulation of patients harboring PDAC or IPMN
The qRT-PCR expression analysis of 17 candidate miRNAs in
plasma samples clearly showed a differential expression profile be-
tween patients with PDAC or IPMN and controls (Figure 1), with
a remarkable overlap between patients with IPMN and PDAC.
From the 17 circulatingmiRNAs analyzed in the final 182 plasma
samples, the following 16 were significantly upregulated in PDAC
compared with the control group: let-7e-5p, let-7f-5p, miR-103a-3p,
miR-151a-5p, miR-151b, miR-16-5p, miR-181a-5p, miR-181b-5p,
miR-192-5p, miR-21-5p, miR-221-3p, miR-23a-3p, miR-320a, miR-
33a-3p, miR-548d-3p, and miR-93-5p. Regarding the comparative
analysis of miRNA expression between IPMN and control plasmas,
14 of 17 miRNAs were also significantly overexpressed: let-7e-5p,
let-7f-5p, miR-103a-3p, miR-151a-5p, miR-151b, miR-16-5p, miR-
181a-5p, miR-192-5p, miR-21-5p, miR-221-3p, miR-23a-3p, miR-
320a, miR-33a-3p, and miR-93-5p. Among them, there were 9
miRNAs (miR-151b, miR-16-5p, miR-181a-5p, miR-192-5p, miR-
21-5p, miR-320a, miR-33a-3p, miR-548d-3p, and miR-93-5p) with
also significant higher levels in CP than in C. Fold change and FDR
values are specified in Table 1, and box plots of all miRNAs analyzed
are depicted in Figure S1 (see Supplementary Digital Content 1,
http://links.lww.com/CTG/A25).
Validated miRNAs in plasma samples show high accuracy to
discriminate between patients with PDAC or IPMN and controls
The diagnostic potential of all miRNAs validated as significantly
upregulated in our plasma set was assessed by ROC analysis. Re-
garding the capacity to discriminate patients with pancreatic
neoplasia (including PDAC or IPMN) from controls, these miR-
NAs presented individually AUC ranging from 0.64 to 0.86. miR-
21-5p, miR-33a-3p, miR-320a, and miR-93-5p were the ones
showing the highest discriminating accuracy (Figure 2 and
Table 2). In addition, the diagnostic capacity to distinguish PDAC
vs controls and IPMNvs controls, separately, is detailed in Table S2
(see Supplementary Digital Content 3, http://links.lww.com/CTG/
A27). Theperformances of these combinations forPDACor IPMN
separately are shown in Table S3 (see Supplementary Digital
Content 4, http://links.lww.com/CTG/A28). It is important to
highlight that the best 4 combinations contained miR-33a-3p.
Signatures combining 2 miRNAs with CA19.9 further improve
the accuracy for diagnosing pancreatic neoplasia
We next examined CA19.9 levels on our set of plasma samples to
see whether adding CA19.9 to these miRNA signatures could
improve diagnostic performance. CA19.9 showed anAUCof 0.85
(95% confidence interval: 0.91–0.79) to discriminate patients
with pancreatic neoplasia from controls.
Addition of CA19.9 to the above-mentioned 2-miRNA sig-
natures clearly improved diagnostic performances reaching AUC
values of 0.95 for the signatures: “miR-33a-3p1miR-
320a1CA19.9,” “miR-33a-3p1miR-211CA19.9,” and “miR-
33a-3p1miR-548-3p1CA19.9” and 0.94 for the signature
“miR-33a-3p1miR-931CA19.9” (Table 3). As we can see, all of
them showed very similar performances with high sensitivity and
specificity to discriminate between patients with PDAC or IPMN
and controls. Among them, we chose to plot the ROC curve from
the signature combining miR-33a-3p and miR-320a plasma ex-
pression levels with CA19.9, for being the one with the highest
AUC, the lowest Brier score (0.079 vs . 0.081), and very high
sensitivities and specificities to detect patients with pancreatic
neoplasia (Figure 3a). Cross-validation for this signature reached
a corrected AUC of 0.939 (0.921–0.952). As we can see in
Figure 3b, plasma samples from control individuals appeared
quite differentiated from PDAC or IPMN samples, depending on
the scaled values of miR-33a-3p, miR-320a, and CA19.9. It is
worth to highlight that in the corresponding multivariate model,
the 3 variables (miR-33a-3p, miR-320a, and CA19.9) are identi-
fied as independent (see Table S4, SupplementaryDigital Content
Figure 1. Circulating miRNA expression profiles distinguish between patients with PDAC or IPMN and control individuals. Heatmap showing expression
profiling by qRT-PCR of 17 candidate miRNAs in plasma samples from PDAC (n 5 94), IPMN (n 5 19), and C (n 5 51). Red pixels correspond to an
increased abundance of miRNA in the indicated sample, whereas green pixels indicate decreased miRNA levels. C, control; IPMN, intraductal papillary
mucinous neoplasm; PDAC, pancreatic ductal adenocarcinoma.
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5, http://links.lww.com/CTG/A29). According to this signature,
only 8.5% of the plasma samples showed a probability risk higher
than 0.5 of beingmisclassified (Figure 3c). Considering the group of
PDAC independently, we observed that the diagnostic power of 2-
miRNA signatures for PDAC improved with the use of CA19.9 (see
Table S3, Supplementary Digital Content 4, http://links.lww.com/
CTG/A28). By contrast, the value of CA19.9 to detect IPMN cases
from controls is lower than all individual miRNAs analyzed with
a poor AUC of 0.62 (see Table S2, Supplementary Digital Content 3,
http://links.lww.com/CTG/A27), and its combination with the best
miRNA signatures does not improve at all the diagnostic perform-
ances of miRNAs (data not shown).
DISCUSSION
In this study, we have shown that analysis of a panel of circulating
miRNAs in plasma fromamulticenter cohort results in a significant
differential expression profile between PDACor IPMNand healthy
individuals.All of themhadbeenpreviously foundoverexpressed in
pancreatic tissue from IPMN and PDAC patients as we had pre-
viously published (11). These results confirm that there is a very
similar miRNA expression pattern between tissue and plasma for
the miRNAs tested.Whether this coincidental trend of alteration is
due to the fact that these circulating cancer-associated miRNAs are
actively secreted from their originating cells, passively released from
necrotic tumor cells, or are mere byproducts of other responses
mediated by the carcinogenesis would require further investigation.
There are a few studieswhichhave already analyzed the relationship
between circulating and tissue miRNAs demonstrating different
sources of circulating miRNAs (15–17).
Several studies have already reported altered expression profiles
of circulating miRNAs in pancreatic cancer (18–21). Early on,
Wang et al. (22) identified miR-21, miR-210, miR-155, and miR-
196a as being upregulated in plasma of PDAC compared with
healthy individuals. Carlsen et al. (23) described a group of 7
deregulatedmiRNAs in PDAC plasmas vs disease controls, and Liu
et al. (24) demonstrated elevated expression of numerous miRNAs
in the serum of pancreatic cancer. However, our study, apart from
confirming already reported aberrantly expressed miRNAs in
PDAC (such as miR-155-5p, miR-16-5p, miR-181a-5p, miR-181b,
miR-192-5p, miR-21-5p, and miR-221-3p), also describes new al-
tered circulating miRNAs in PDAC that have never been reported
before (let-7e-5p, let-7f-5p, miR-103a-3p, miR-151a-5p, miR-151b,
miR-23-3p, miR-320a, miR-33a-3p, miR-548d-3p, and miR-93).
Besides, most of them have never been reported as altered in IPMN
cases (25,26).
IPMNs, the only radiographically identifiable precursor
lesions of pancreatic cancer, have the potential to progress into
invasive carcinoma. Approximately 30% of IPMNs that are sur-
gically resected ultimately demonstrate invasive disease (27).
Detecting them before its malignant transformation is crucial for
patient survival. However, the identification of high-grade dys-
plasia and early invasive carcinoma and the timing and frequency
of malignant progression remain a critical issue in the manage-
ment of these patients (28). Permuth-wey et al. (29) defined
a 5-miRNA signature that discriminated between malignant and
benign IPMNs, supporting miRNA relevance in the progression
of IPMNs to malignancy. In the clinical practice, only carci-
noembryonic antigen and CA.19.9 are used regardless of their
very low sensitivities concerning malignant IPMNs. Better mo-
lecular knowledge of these lesions and new biomarkers are re-
quired to identify those individuals who will benefit from an early
surgery and those who will benefit from surveillance (30).
Table 1. FC and FDR of 17miRNAs expression in PDAC (n594) vs C (n551), IPMN (n519) vs C (n551), and CP (n5 18) vs C (n551)
plasma samples
miRNA FC PDAC vs C FDR PDAC vs C FC IPMN vs C FDR IPMN vs C FC CP vs C FDR CP vs C
hsa-let-7e-5p 1.49 1.74E-02 1.92 1.92E-02 1.41 1.89E-01
hsa-let-7f-5p 1.84 4.63E-03 2.25 2.31E-02 1.62 1.42E-01
hsa-miR-103a-3p 1.84 1.12E-03 3.43 4.57E-04 1.45 3.02E-01
hsa-miR-151a-5p 1.79 7.60E-04 2.72 1.34E-03 1.58 1.50E-01
hsa-miR-151b 1.95 5.07E-05 2.70 8.03E-04 2.27 2.52E-03
hsa-miR-155-5p 1.26 2.03E-01 1.75 7.60E-02 2.15 6.16E-02
hsa-miR-16-5p 2.12 3.06E-05 3.04 3.53E-04 2.04 2.44E-02
hsa-miR-181a-5p 1.87 2.55E-04 2.57 2.06E-03 1.94 2.52E-02
hsa-miR-181b-5p 4.57 4.19E-03 4.18 1.00E-01 3.78 2.31E-01
hsa-miR-192-5p 3.57 6.80E-07 2.60 1.19E-03 3.84 1.78E-03
hsa-miR-21-5p 3.19 1.41E-07 2.95 3.25E-04 2.91 3.48E-04
hsa-miR-221-3p 2.35 5.92E-04 2.65 1.45E-02 1.55 2.24E-01
hsa-miR-23a-3p 1.71 1.83E-03 1.64 2.45E-02 1.30 2.54E-01
hsa-miR-320a 2.65 3.83E-07 3.54 2.11E-04 3.10 5.56E-04
hsa-miR-33a-3p 37.23 4.93E-08 25.69 8.00E-04 32.33 5.37E-04
hsa-miR-548d-3p 3.29 1.01E-03 2.86 7.04E-02 4.75 1.34E-02
hsa-miR-93-5p 2.21 4.84E-06 3.79 2.73E-04 2.54 7.37E-03
CP, chronic pancreatitis; FC, fold change; FDR, false discovery rate; IPMN, intraductal papillary mucinous neoplasm; miRNA, microRNA; PDAC, pancreatic ductal
adenocarcinoma.









Herein, among the 17 miRNAs analyzed, we have identified
a panel of 14 circulating miRNAs significantly overexpressed in
the plasma of both patients with PDAC and IPMN relative to
control individuals, suggesting that they could serve as potential
noninvasive biomarkers indicative of a neoplastic process in the
pancreas. Two other miRNAs, miR-181b-5p and miR-548d-3p,
were significantly upregulated in PDAC plasmas but not in pre-
malignant IPMNs, suggesting that their late increase in levels
could be related to themalignant progression of IPMNs.Whether
these 2 miRNAs could be specific of invasive or high-risk IPMNs
and could serve to distinguish between low- and high-risk IPMNs
should be confirmed in subsequent studies designed for this
purpose. Moreover, these results have to be taken with a cautious
note because the group of IPMN samples is small, and further
studies also including malignant IPMN would be required to
confirm these molecules as involved in malignant trans-
formation. Regarding the CP group, 6 miRNAs significantly al-
tered in IPMN and PDAC (let-7e-5p, let-7f-5p, miR-103a-3p,
miR-151a-5p, miR-221-3p, and miR-23a-3p) had normal levels
in CP plasmas, suggesting that these 6 miRNAs could be more
specific of pancreatic neoplasia. However, these results should be
validated in larger cohorts of patients.
Several studies have reported that levels of circulating miRNAs
in combination with CA19.9 work efficiently for screening
pancreatic cancer. Liu et al. (26) concluded that the combination of
miR-16, miR-196a, and CA19.9 was more effective among various
combinations in discriminating patients with PDAC from patients
without PDAC. Schultz et al. (31) observed that amiRNA panel for
diagnosing PDAC, tested in whole blood, could be more useful in
combination with serum CA19.9. In accordance, we have demon-
strated that addition of CA19.9 to the bestmiRNA signatures in our
plasma set improves the overall diagnostic performance. Combi-
nation of the miRNAs found here and other new blood-based
biomarkers as circulating tumor DNA or circulating tumor cells
could be additionally studied to try to further enhance surveillance
for invasive PDAC.
We describe here, for the first time, the signature “miR-33a-
3p1miR-320a” able to discriminate patients harboring malignant
pancreatic cancer or premalignant IPMNs from healthy individ-
uals with high accuracy (88% sensitivity and 82% specificity), and
additionofCA19.9 increases this performance (93% sensitivity and
85% specificity), suggesting that this combination could be
a promising biomarker signature for noninvasive early detection of
pancreatic neoplasia.
Nevertheless, before we can translate miRNA expression
evaluation into a clinical routine, it is necessary to standardize the
methodologies used. A comprehensive review of circulating
miRNAs by Jarry et al. (32) unveils great contradictions in the
Figure2.PlasmamiR-21-5p,miR-33a-3p,miR-320a, andmiR-93-5ppresent a highcapacity to distinguishpatientswith pancreatic neoplasia fromcontrol
individuals. ROC curves of the top 4 miRNAs illustrating high discriminatory power to detect pancreatic neoplasia (PDAC or IPMN). Results are obtained
from miRNA analysis by qRT-PCR in PDAC or IPMN (n 5 113) and C (n5 51) plasma samples. AUC, area under the curve.
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results and low levels of reproducibility across different labora-
tories that have used different methods.
Nonetheless, it is noteworthy that the results presented here
could help detecting pancreatic malignant lesions in asymp-
tomatic stages, even before malignancy, helping to improve the
fatal prognosis and life expectancy of this disease. We can also
consider that a test like this could be useful for early diagnosis
likely on suspicion of pathology; for that purpose, the behavior
of these biomarkers in other pancreatic pathologies and tumor
types such as solid pseudopapillary neoplasm and neuroendo-
crine tumors should be further studied, given that they have
a different clinical management. Determining the functional
role of miRNAs in circulation is critical to their advancement as
suitable biomarkers (33). In further studies, we aim to elucidate
the biological implication of these miRNAs in PDAC. It is im-
portant to note that most of the plasmatic miRNAs that we have
found deregulated in pancreatic cancer are already described to
be associated with tumor biology (34), and others have not been
studied yet.
CONCLUSIONS
Wehave found a panel of altered circulatingmiRNAs that hold
great promise as a proof of principle for PDAC noninvasive
early detection. In addition, we have defined a biomarker
Table 3. Summary data from ROC curve analysis of the 4 top 2-miRNA signatures for detecting pancreatic neoplasia (PDAC or IPMN) from
plasma samples and their values when combined with CA19.9 (adjusted by age and sex)
2-miRNA signature
AUC (PDAC 1
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miR-33a-3p1miR-320a 0.90 0.96–0.85 88 82 92 75 0.95 0.98–0.92 93 85 94 83
miR-33a-3p1miR-21 0.89 0.95–0.84 88 82 92 76 0.95 0.98–0.91 90 87 94 79
miR-33a-3p1miR-548d-3p 0.88 0.95–0.82 82 81 89 71 0.95 0.98–0.92 90 87 93 81
miR-33a-3p1miR-93 0.88 0.94–0.81 84 82 91 70 0.94 0.98–0.90 93 85 94 83
SN and SP cutoff considered the minimum distance between the ROC curve and upper left corner.
AUC, area under the curve; CI, confidence interval; IPMN, intraductal papillarymucinous neoplasm;miRNA,microRNA; NPV, negative predictive value; PDAC, pancreatic
ductal adenocarcinoma; PPV, positive predictive value; ROC, receiver operating characteristic; SN, sensitivity; SP, specificity.
Table 2. Summary data fromROC curve analysis of all miRNAs analyzed in plasma samples from patients with pancreatic neoplasia (PDAC
or IPMN, n 5 113) and control individuals (n 5 51)
miRNA AUC (PDAC 1 IPMN vs C) 95% CI SN (%) SP (%) PPV (%) NPV (%)
hsa-let-7e-5p 0.64 0.56–0.73 70 55 77 45
hsa-let-7f-5p 0.72 0.64–0.80 65 77 86 49
hsa-miR-103a-3p 0.75 0.68–0.83 75 73 86 57
hsa-miR-151a-5p 0.64 0.56–0.73 71 55 78 46
hsa-miR-151b 0.78 0.71–0.85 69 77 87 53
hsa-miR-155-5p 0.67 0.58–0.75 50 84 88 43
hsa-miR-16-5p 0.77 0.70–0.85 70 77 87 53
hsa-miR-181a-5p 0.75 0.68–0.83 68 80 89 53
hsa-miR-181b-5p 0.72 0.64–0.80 64 69 83 46
hsa-miR-192-5p 0.65 0.56–0.74 71 55 78 46
hsa-miR-21-5p 0.86 0.80–0.92 82 78 89 67
hsa-miR-221-3p 0.64 0.55–0.73 71 54 78 45
hsa-miR-23a-3p 0.73 0.65–0.81 70 67 82 50
hsa-miR-320a 0.85 0.79–0.92 81 82 91 67
hsa-miR-33a-3p 0.85 0.77–0.92 81 78 89 65
hsa-miR-548d-3p 0.76 0.67–0.85 69 76 84 57
hsa-miR-93-5p 0.80 0.73–0.87 76 75 87 59
Models are adjusted by age and sex.
SN and SP cutoff considered the minimum distance between the ROC curve and upper left corner.
AUC, area under the curve; CI, confidence interval; IPMN, intraductal papillarymucinous neoplasm;miRNA,microRNA; NPV, negative predictive value; PDAC, pancreatic
ductal adenocarcinoma; PPV, positive predictive value; ROC, receiver operating characteristic; SN, sensitivity; SP, specificity.









Figure 3. Performance of the best plasma miRNA signature to discriminate between patients with pancreatic neoplasia and control individuals in our
plasma set. (a) Receiver operating characteristic curve of the top miRNA signature “miR-33a-3p1miR-320a” to detect pancreatic neoplasia (PDAC or
IPMN). Results are obtained from miRNA analysis by qRT-PCR in PDAC or IPMN (n5 113) and C (n 5 51) plasma samples. CA19.9 diagnostic
performance for patients with pancreatic neoplasia and its combination with the above-mentioned miRNA signature are also shown. (b) Scatter graph
according to the scaled values of miR-33a-3p, miR-320a, and CA19.9 for PDAC, IPMN, and C plasma set (n5 182). (c) Probabilistic sensitivity analysis
according to the plasma signature “miR-33a-3p1miR-320a1CA19.9.” AUC, area under the curve; C, control; IPMN, intraductal papillary mucinous
neoplasm; PDAC, pancreatic ductal adenocarcinoma.
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signature consisting of 2 miRNAs combined with CA19.9 to
detect pancreatic neoplasia with the highest diagnostic values
reported to date. However, before these novel biomarkers can
be routinely used in a clinical setting, it is essential to validate
them in larger cohorts of patients by using standardized
approaches to the isolation, quantification, and miRNA nor-
malization to ensure reproducibility.
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